Table 4.
Cross-reactivities of commercial enzyme immunoassay kits and IACs for masked mycotoxins
| Commercial kit | Supplier | Studied cross-reacting masked mycotoxin | Cross- reactivity (%) | Reference |
|---|---|---|---|---|
| ELISA | ||||
| Ridascreen® DON | R-Biopharm | D3G | 82–98 | [92] |
| Agraquant® | RomerLabs | D3G | 52 | [124] |
| DON EIA® | Europroxima | D3G | 115 | [124] |
| Veratox® | Neogen Corp. | D3G | 157 | [124] |
| Rosa LF-DONQ® (LFD) | Charm | D3G | 8 | [124] |
| MycontrolDON® (Fluorescence | Aokin | D3G | 22 | [124] |
| polarisation IA) | ||||
| Ridascreen® fumonisin | R-Biopharm | Hydrolyzed FB1 | 0 | [67] |
| Ridascreen® fumonisin | R-Biopharm | Protein extract containing bound fumonisins | Positive for all analytes, but not quantified | [67] |
| IAC | ||||
| DON-Prep® | R-Biopharm | D3G, Z14G, α-ZELG, β-ZELG, Z14S | 0 | [101] |
| DON test® | Vicam | D3G, Z14G, α-ZELG, β-ZELG, Z14S | 0 | [101] |
| Easi-extract® ZEN | R-Biopharm | D3G, Z14G, α-ZELG, β-ZELG, Z14S | 0 | [101] |
| Zearatest® | Vicam | D3G, Z14G, α-ZELG, β-ZELG, Z14S | 0 | [101] |
| Zearastar® | RomerLabs | D3G, Z14G, α-ZELG, β-ZELG, Z14S | 0 | [101] |
| DON-Prep® | R-Biopharm | D3G, Z14G | 58, 0 | [125]a) |
| NeoColumn® DON | Neogen Corp. | D3G, Z14G | 48, 0 | [125]a) |
| ImmunoClean® C DON | Aokin | D3G, Z14G | 0 | [125]a) |
| Easi-extract® ZEN | R-Biopharm | D3G, Z14G | 0 | [125]a) |
| NeoColumn® ZEN | Neogen Corp. | D3G, Z14G | 0 | [125]a) |
| ImmunoClean® C ZEN | Aokin | D3G, Z14G | 0 | [125]a) |
| DZT® MS-prep | R-Biopharm | D3G, Z14G | 41, 0 | [125]a) |
a)
Further tested mycotoxins were: 3ADON, 15ADON, DON-3-glucuronide, ZEN-glucuronide, deepoxy-DON, α-ZEL, β-ZEL and nivalenol.